AR121649A1 - Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos - Google Patents
Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usosInfo
- Publication number
- AR121649A1 AR121649A1 ARP210100729A ARP210100729A AR121649A1 AR 121649 A1 AR121649 A1 AR 121649A1 AR P210100729 A ARP210100729 A AR P210100729A AR P210100729 A ARP210100729 A AR P210100729A AR 121649 A1 AR121649 A1 AR 121649A1
- Authority
- AR
- Argentina
- Prior art keywords
- deletion
- ala
- ser
- lys
- gly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente divulgación proporciona compuestos peptídicos agonistas del receptor de GIP para dosificación una vez por semana (QW), en los que dichos compuestos peptídicos tienen una acción activadora sobre los receptores de GIP, y el uso del péptido agonista del receptor GIP como medicamento para el tratamiento y/o la prevención de la emesis o un síntoma o una afección asociados con la emesis. Específicamente, se proporciona un péptido agonista del receptor de GIP que contiene una secuencia representada por cualquiera de las formulas (1) - (5) o una sal de este y un medicamento que lo comprende. Reivindicación 1: Un péptido agonista del receptor de GIP representado por la fórmula (1): P¹-Tyr-A²-Glu-Gly-Thr-Phe-Ile-Ser-A⁹-Tyr-Ser-Ile-A¹³-A¹⁴-Asp-A¹⁶-A¹⁷-A¹⁸-Gln-A²⁰-A²¹-Phe-Val-A²⁴-Trp-Leu-Leu-Ala-Gln-A³⁰-A³¹-A³²-A³³-A³⁴-A³⁵-A³⁶-A³⁷-A³⁸-A³⁹-A⁴⁰-A⁴¹-A⁴²-P² o una sal farmacéuticamente aceptable de este; donde P¹ representa un grupo representado por la fórmula -RA¹, -CO-RA¹, -CO-ORA¹, -CO-CORA¹, -SO-RA¹, -SO₂-RA¹, -SO₂-ORA¹, -CO-NRA²RA³, -SO₂-NRA²RA³, -C(=NRA¹)-NRA²RA³, o está ausente, en donde cada uno de RA¹, RA² y RA³ representa independientemente un átomo de hidrógeno, un grupo hidrocarburo opcionalmente sustituido o un grupo heterocíclico opcionalmente sustituido; P² representa -NH₂ u -OH; A²: representa Aib, D-Ala, Ala, Gly o Pro; A⁹: representa Asp o Leu; A¹³: representa Aib o Ala; A¹⁴: representa Leu, Aib, Ile o Nle; A¹⁶: representa Arg, Ser o Lys; A¹⁷: representa Aib, Ala o Ile; A¹⁸: representa Ala, His o Lys; A¹⁹: representa Gln o Ala; A²⁰: representa Aib, Gln o Ala; A²¹: representa Asp, Asn o Lys; A²⁴: representa Asn, Gln o Glu; A³⁰: representa Arg, Ser, Gln o Lys; A³¹: representa Gly, Pro o una deleción; A³²: representa Ser, Lys, Pro, Gly o una deleción; A³³: representa Ser, Lys, Gly o una deleción; A³⁴: representa Gly, Asn o una deleción; A³⁵: representa Ala, Asp, Ser, Asn o una deleción; A³⁶: representa Pro, Trp o una deleción; A³⁷: representa Pro, Lys o una deleción; A³⁸: representa Pro, His o una deleción; A³⁹: representa Ser, Asn o una deleción; A⁴⁰: representa Ile o una deleción; A⁴¹: representa Thr o una deleción; y A⁴²: representa Gln, o una deleción.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062994721P | 2020-03-25 | 2020-03-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR121649A1 true AR121649A1 (es) | 2022-06-22 |
Family
ID=75674909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210100729A AR121649A1 (es) | 2020-03-25 | 2021-03-25 | Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos |
Country Status (17)
Country | Link |
---|---|
US (1) | US20230143604A1 (es) |
EP (1) | EP4126920A2 (es) |
JP (1) | JP2023524603A (es) |
KR (1) | KR20220157409A (es) |
CN (1) | CN115916812A (es) |
AR (1) | AR121649A1 (es) |
AU (1) | AU2021243671A1 (es) |
BR (1) | BR112022019110A2 (es) |
CA (1) | CA3172241A1 (es) |
CL (1) | CL2022002597A1 (es) |
CO (1) | CO2022014960A2 (es) |
EC (1) | ECSP22074715A (es) |
IL (1) | IL296219A (es) |
MX (1) | MX2022011729A (es) |
PE (1) | PE20221727A1 (es) |
TW (1) | TW202202517A (es) |
WO (1) | WO2021193983A2 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023139106A2 (en) * | 2022-01-18 | 2023-07-27 | Novo Nordisk A/S | Long-acting gipr antagonists |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0862562B1 (en) | 1995-09-13 | 2001-07-04 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
CA2416384A1 (en) | 2000-07-17 | 2003-01-16 | Takeda Chemical Industries, Ltd. | Sulfone derivatives, their production and use |
NZ540381A (en) | 2002-11-01 | 2007-11-30 | Takeda Pharmaceutical | 5-membered aromatic heterocycle derivatives as prophylactic and therapeutic agents for treating neuropathy |
WO2004041266A1 (ja) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
WO2004048363A1 (ja) | 2002-11-22 | 2004-06-10 | Takeda Pharmaceutical Company Limited | イミダゾール誘導体、その製造法および用途 |
EP1630152A4 (en) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONNECTION WITH CONDENSED RING |
US7534887B2 (en) | 2003-09-30 | 2009-05-19 | Takeda Pharmaceutical Company Limited | Thiazoline derivative and use of the same |
CA2550012A1 (en) | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | Urea derivative, process for producing the same and use |
BRPI0418148A (pt) | 2003-12-25 | 2007-04-17 | Takeda Pharmaceutical | composto, prodroga de um composto, modulador da função do receptor gpr40, agente farmacêutico, uso de um composto e métodos de modificação de uma função do receptor gpr40 em um mamìfero, de profilaxia ou tratamento de diabetes em um mamìfero e de produção de um composto |
JP4855777B2 (ja) | 2003-12-26 | 2012-01-18 | 武田薬品工業株式会社 | フェニルプロパン酸誘導体 |
JP4875978B2 (ja) | 2004-03-15 | 2012-02-15 | 武田薬品工業株式会社 | アミノフェニルプロパン酸誘導体 |
WO2005095338A1 (ja) | 2004-03-30 | 2005-10-13 | Takeda Pharmaceutical Company Limited | アルコキシフェニルプロパン酸誘導体 |
TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
US8263545B2 (en) * | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
EP2308839B1 (en) | 2005-04-20 | 2017-03-01 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
EP1916234B1 (en) | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
JPWO2007013694A1 (ja) | 2005-07-29 | 2009-02-12 | 武田薬品工業株式会社 | フェノキシアルカン酸化合物 |
CA2617969A1 (en) | 2005-08-10 | 2007-02-15 | Takeda Pharmaceutical Company Limited | Therapeutic agent for diabetes |
JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
ME00535B (me) | 2006-06-27 | 2011-10-10 | Takeda Pharmaceuticals Co | Fuzionisana ciklična jedinjenja |
CA2660835A1 (en) * | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | Dpp-iv resistant gip hybrid polypeptides with selectable propperties |
US8492405B2 (en) | 2006-10-18 | 2013-07-23 | Takeda Pharmaceutical Company Limited | Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity |
NZ576570A (en) | 2006-10-19 | 2010-11-26 | Takeda Pharmaceutical | 7-sulfonylamino-2-thiazol and 2-thiadiazol -indole compounds |
WO2008093639A1 (ja) | 2007-01-29 | 2008-08-07 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
WO2008099794A1 (en) | 2007-02-09 | 2008-08-21 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of ppar-gamma |
JPWO2008136428A1 (ja) | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素5員複素環化合物 |
WO2008156757A1 (en) | 2007-06-19 | 2008-12-24 | Takeda Pharmaceutical Company Limited | Indazole compounds for activating glucokinase |
WO2010016936A1 (en) * | 2008-08-07 | 2010-02-11 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide |
KR20130133103A (ko) * | 2008-08-07 | 2013-12-05 | 입센 파마 에스.에이.에스 | N-말단이 변형된 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드(gip)의 유사체 |
JOP20180028A1 (ar) * | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
-
2021
- 2021-03-25 MX MX2022011729A patent/MX2022011729A/es unknown
- 2021-03-25 CA CA3172241A patent/CA3172241A1/en active Pending
- 2021-03-25 US US17/914,013 patent/US20230143604A1/en active Pending
- 2021-03-25 CN CN202180023693.4A patent/CN115916812A/zh active Pending
- 2021-03-25 AU AU2021243671A patent/AU2021243671A1/en active Pending
- 2021-03-25 AR ARP210100729A patent/AR121649A1/es unknown
- 2021-03-25 KR KR1020227034445A patent/KR20220157409A/ko unknown
- 2021-03-25 IL IL296219A patent/IL296219A/en unknown
- 2021-03-25 WO PCT/JP2021/014422 patent/WO2021193983A2/en active Application Filing
- 2021-03-25 EP EP21721645.6A patent/EP4126920A2/en active Pending
- 2021-03-25 JP JP2023502028A patent/JP2023524603A/ja active Pending
- 2021-03-25 PE PE2022002091A patent/PE20221727A1/es unknown
- 2021-03-25 BR BR112022019110A patent/BR112022019110A2/pt unknown
- 2021-03-25 TW TW110110875A patent/TW202202517A/zh unknown
-
2022
- 2022-09-23 CL CL2022002597A patent/CL2022002597A1/es unknown
- 2022-09-23 EC ECSENADI202274715A patent/ECSP22074715A/es unknown
- 2022-10-20 CO CONC2022/0014960A patent/CO2022014960A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021193983A8 (en) | 2023-05-25 |
EP4126920A2 (en) | 2023-02-08 |
ECSP22074715A (es) | 2022-10-31 |
CN115916812A (zh) | 2023-04-04 |
JP2023524603A (ja) | 2023-06-12 |
AU2021243671A1 (en) | 2022-10-13 |
PE20221727A1 (es) | 2022-11-04 |
MX2022011729A (es) | 2022-10-13 |
IL296219A (en) | 2022-11-01 |
WO2021193983A3 (en) | 2021-11-04 |
BR112022019110A2 (pt) | 2023-01-17 |
WO2021193983A2 (en) | 2021-09-30 |
TW202202517A (zh) | 2022-01-16 |
CO2022014960A2 (es) | 2022-11-08 |
CA3172241A1 (en) | 2021-09-30 |
KR20220157409A (ko) | 2022-11-29 |
CL2022002597A1 (es) | 2023-06-02 |
US20230143604A1 (en) | 2023-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR096440A1 (es) | Compuesto peptídico agonista del receptor del péptido similar al glucagón tipo i (glp-1) y del péptido insulinotrópico dependiente de glucosa (gip) | |
CO2020014180A2 (es) | Derivados de gip y usos de estos | |
Sarhan et al. | Crystallographic basis for calcium regulation of sodium channels | |
PE20160991A1 (es) | Bioconjugados de polipeptidos de apelina sintetica | |
Carstens et al. | Structure–Activity Studies of Cysteine‐Rich α‐Conotoxins that Inhibit High‐Voltage‐Activated Calcium Channels via GABAB Receptor Activation Reveal a Minimal Functional Motif | |
AR094181A1 (es) | Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon | |
AR112480A1 (es) | Composiciones de glp-1 y sus usos | |
PE20220938A1 (es) | Compuestos agonistas de gipr | |
RU2014101697A (ru) | Коагонисты рецепторов глюкагона/glp-1 | |
AR049940A1 (es) | Uso de compuestos peptidicos para tratar tremor esencial y otros sindromes de tremor | |
AR096162A1 (es) | Péptidos terapéuticos | |
CO2021006482A2 (es) | Ureas cíclicas | |
RU2017106172A (ru) | Применение антагонистов cxcr2 для предотвращения и/или лечения периферической невропатии, вызванной химиотерапией (cipn) | |
AR121649A1 (es) | Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos | |
CL2020002574A1 (es) | Análogos novedosos de glp-1 | |
PE20210116A1 (es) | Administracion oral de analogos del peptido glp-1 | |
CL2019003441A1 (es) | Puestos de mic-1 y usos de estos. | |
AR121650A1 (es) | Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usos | |
PE20200150A1 (es) | Uso de antagonistas de klk5 para el tratamiento de una enfermedad | |
AR068521A1 (es) | Derivados heterociclicos triciclicos | |
UY38067A (es) | Péptidos de la cadena b de la relaxina modificados y su uso terapéutico | |
AR105269A1 (es) | Péptidos y derivados de péptidos de colecistoquinina (cck) y sus usos | |
ECSP22037660A (es) | Agonistas del receptor npy2 | |
AR109688A1 (es) | Compuestos de indazol para uso en lesiones de tendones y/o ligamentos | |
CL2023000090A1 (es) | Coagonistas de los receptores de glp-1 y gip |